Therapy Areas: Infectious Diseases
Muna Therapeutics names new independent Chair of Board of Directors
14 September 2021 -

Muna Therapeutics, a company pioneering first-in-class small molecule therapeutics for neurodegenerative diseases, announced on Monday that it has named Dr Donald Nicholson as an independent chair of its board of directors.

Dr Nicholson has experience in biotech and large pharma. He has earlier served as the CEO of Nimbus Therapeutics, and for 25 years at Merck, where he held various strategic, leadership and operational roles across diverse therapeutic areas. He started his career at Merck Frosst in Montreal as a senior research biologist, rising to vice president and site head of the Merck Neurosciences Research site in San Diego, vice president of immunology and infectious diseases and vice president and worldwide discovery head for the Bone, Respiratory, Immunology and Endocrine franchise based in New Jersey. He is currently chair of the board of directors at NodThera, Disc Medicine and Jnana Therapeutics, and board director at Kymera Therapeutics and Generation Bio.

Rita Balice-Gordon, chief executive officer of Muna Therapeutics, said, 'We are delighted to welcome Dr Nicholson as independent chair at Muna. He brings to Muna a wealth of experience in biopharma and biotech, insights into building high-functioning companies and boards, and a commitment to advancing therapies for patients with neurodegenerative diseases. We look forward to working with him and the Board as we move forward.'



Related Headlines